Evidence map›Paper›PMID 37096888›Full record

ArticleCancer2023

Plasma levels of interleukin-6 mediate neurocognitive performance in older breast cancer survivors: The Thinking and Living With Cancer study.

Jeanne S Mandelblatt, Brent J Small, Xingtao Zhou, Zev M Nakamura, Harvey J Cohen, Tim A Ahles, Jaeil Ahn, Traci N Bethea, Martine Extermann, Deena Graham and 13 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
4.7field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 18 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors at 11 institutions in 1 country.

Jeanne S MandelblattDepartment of Oncology, Georgetown University Medical Center, Georgetown University, Washington, DC, USA.ORCID 0000-0002-2490-005X
Brent J SmallSchool of Aging Studies, University of South Florida, Tampa, Florida, USA.
Xingtao ZhouDepartment of Biostatistics, Bioinformatics, and Biomathematics, Department of Oncology and Georgetown Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, USA.ORCID 0000-0002-5164-125X
Zev M NakamuraDepartment of Psychiatry, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.ORCID 0000-0001-9695-1457
Harvey J CohenDepartment of Medicine, Duke University Medical Center, Durham, North Carolina, USA.
Tim A AhlesDepartment of Psychiatry and Behavioral Sciences, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Jaeil AhnDepartment of Biostatistics, Bioinformatics, and Biomathematics, Department of Oncology and Georgetown Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, USA.
Traci N BetheaDepartment of Oncology, Georgetown University Medical Center, Georgetown University, Washington, DC, USA.ORCID 0000-0003-3205-2078
Martine ExtermannDepartment of Oncology, H. Lee Moffitt Cancer Center and Research Institute, University of South Florida, Tampa, Florida, USA.ORCID 0000-0003-4381-1199
Deena GrahamJohn Theurer Cancer Center, Hackensack University Medical Center, Hackensack, New Jersey, USA.
Claudine IsaacsGeorgetown Lombardi Comprehensive Cancer Center, Department of Oncology, Department of Medicine, Georgetown University, Washington, DC, USA.
Paul B JacobsenHealthcare Delivery Research Program, Division of Cancer Control and Population Sciences, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
Heather S L JimCancer Prevention and Control Program, H. Lee Moffitt Comprehensive Cancer Center, Tampa, Florida, USA.ORCID 0000-0001-7353-3711
Brenna C McDonaldDepartment of Radiology and Imaging Sciences, Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, Indiana, USA.
Sunita K PatelCity of Hope National Medical Center, Los Angeles, California, USA.ORCID 0000-0002-9023-8391
Kelly E RentscherDepartment of Psychiatry and Behavioral Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.ORCID 0000-0003-1887-3953
James C RootDepartment of Psychiatry and Behavioral Sciences, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Andrew J SaykinDepartment of Radiology and Imaging Sciences, Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, Indiana, USA.
Danielle B TometichCancer Prevention and Control Program, H. Lee Moffitt Comprehensive Cancer Center, Tampa, Florida, USA.
Kathleen Van DykSemel Institute for Neuroscience and Human Behavior, Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California, USA.ORCID 0000-0003-1500-930X
Wanting ZhaiDepartment of Biostatistics, Bioinformatics, and Biomathematics, Department of Oncology and Georgetown Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, USA.
Elizabeth C BreenSemel Institute for Neuroscience and Human Behavior, Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California, USA.
Judith E CarrollSemel Institute for Neuroscience and Human Behavior, Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California, USA.ORCID 0000-0001-5516-0819
Georgetown University · USUniversity of California, Los Angeles · USIndiana University Health · USMemorial Sloan Kettering Cancer Center · USMoffitt Cancer Center · USUniversity of South Florida · USCity Of Hope National Medical Center · USDuke University · USHackensack University Medical Center · USNational Institutes of Health · USUniversity of North Carolina at Chapel Hill · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI SELWYN M VICKERS · 1985 to 2026
$347.4M
Tissue Culture Shared ResourceP30CA051008 · NCI · GEORGETOWN UNIVERSITY · PI MARCUS S NOEL · 1990 to 2026
$71.5M
Research Education ComponentP30AG010133 · NIA · INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS · PI SAYKIN, ANDREW J · 1991 to 2020
$37.3M
Training and Career Development CoreU54CA132378 · NCI · CITY COLLEGE OF NEW YORK · PI Tim Alan Ahles, ADRIANA ESPINOSA · 2008 to 2026
$28.9M
Training and Career Development and Education CoreU54CA137788 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Daniel Alan Heller · 2008 to 2026
$28.1M
Resource Core 3 - Metabolomics CoreP30AG028716 · NIA · DUKE UNIVERSITY · PI CATHLEEN S COLON-EMERIC, Susan Nicole Hastings · 2006 to 2026
$24.6M
Research Education ComponentP30AG072976 · NIA · INDIANA UNIVERSITY INDIANAPOLIS · PI ANDREW J SAYKIN · 2021 to 2026
$24.1M
OLDER BREAST CANCER PATIENTS: RISK FOR COGNITIVE DECLINER01CA129769 · NCI · GEORGETOWN UNIVERSITY · PI AHLES, TIM ALAN, MANDELBLATT, JEANNE · 2009 to 2020
$7.3M
Bio-behavioral Research At The Intersection of Cancer and AgingR35CA197289 · NCI · GEORGETOWN UNIVERSITY · PI MANDELBLATT, JEANNE · 2015 to 2021
$6.2M
Leveraging Digital Health Solutions to Reduce Learning and Functional Disparities in Children with Cancer - Diversity SupplementR01CA261793 · NCI · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI Sunita K Patel · 2022 to 2026
$3.9M
Assessment of sensory gating, attention, and executive control in breast cancerR01CA218496 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI AHLES, TIM ALAN, ROOT, JAMES C · 2018 to 2022
$3.5M
Cognition In Older Breast Cancer Survivors: Treatment Exposure, APOE, & SmokingR01CA172119 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI AHLES, TIM ALAN, HURRIA, ARTI · 2013 to 2017
$3.5M
NCI NIH HHS CA008748NCI NIH HHS CA129769NCI NIH HHS CA137788NCI NIH HHS CA172119NCI NIH HHS CA197289NCI NIH HHS CA212056NCI NIH HHS CA237535NCI NIH HHS CA241337NCI NIH HHS CA244673NCI NIH HHS CA261793NCI NIH HHS CA270294NCI NIH HHS CA51008NCI NIH HHS K01 CA212056NCI NIH HHS K08 CA241337NCI NIH HHS K99 CA270294NCI NIH HHS P30 CA008748NCI NIH HHS P30 CA051008NCI NIH HHS R00 CA270294NCI NIH HHS R01 CA129769NCI NIH HHS R01 CA172119NCI NIH HHS R01 CA218496NCI NIH HHS R01 CA237535NCI NIH HHS R01 CA244673NCI NIH HHS R01 CA261793NCI NIH HHS R35 CA197289NCI NIH HHS U54 CA132378NCI NIH HHS U54 CA137788NIA NIH HHS AG010133NIA NIH HHS AG028716NIA NIH HHS AG068086NIA NIH HHS AG072976NIA NIH HHS K01 AG065485NIA NIH HHS P30 AG010133NIA NIH HHS P30 AG028716NIA NIH HHS P30 AG072976NIA NIH HHS R01 AG068193NIA NIH HHS R01 AG082348NIA NIH HHS R56 AG068086NIH HHS P30CA51008
6 · The paper itself

Abstract

backgroundImmune activation/inflammation markers (immune markers) were tested to explain differences in neurocognition among older breast cancer survivors versus noncancer controls.

methodsWomen >60 years old with primary breast cancer (stages 0-III) (n = 400) were assessed before systemic therapy with frequency-matched controls (n = 329) and followed annually to 60 months; blood was collected during annual assessments from 2016 to 2020. Neurocognition was measured by tests of attention, processing speed, and executive function (APE). Plasma levels of interleukin-6 (IL-6), IL-8, IL-10, tumor necrosis factor α (TNF-α), and interferon γ were determined using multiplex testing. Mixed linear models were used to compare results of immune marker levels by survivor/control group by time and by controlling for age, racial/ethnic group, cognitive reserve, and study site. Covariate-adjusted multilevel mediation analyses tested whether survivor/control group effects on cognition were explained by immune markers; secondary analyses examined the impact of additional covariates (e.g., comorbidity and obesity) on mediation effects.

resultsParticipants were aged 60-90 years (mean, 67.7 years). Most survivors had stage I (60.9%) estrogen receptor-positive tumors (87.6%). Survivors had significantly higher IL-6 levels than controls before systemic therapy and at 12, 24, and 60 months (p ≤ .001-.014) but there were no differences for other markers. Survivors had lower adjusted APE scores than controls (p < .05). Levels of IL-6, IL-10, and TNF-α were related to APE, with IL-6 explaining part of the relationship between survivor/control group and APE (p = .01). The magnitude of this mediation effect decreased but remained significant (p = .047) after the consideration of additional covariates.

conclusionsOlder breast cancer survivors had worse long-term neurocognitive performance than controls, and this relationship was explained in part by elevated IL-6.

Indexed as

Breast NeoplasmsCancer SurvivorsHominidaeAgedBiomarkersCognitionFemaleHumansInterleukin-10Interleukin-6Middle AgedTumor Necrosis Factor-alphaBiomarkersIL6 protein, humanInterleukin-10Interleukin-6Tumor Necrosis Factor-alphabreast cancercancer-related cognitive declinecognitionimmune activationinflammationolder survivors

Identifiers

PMID37096888
PMCPMC10750797
OpenAlexW4366985156

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.